The Company's cellular product manufactured in accordance with the methodologies described in this newly issued patent meets rigorous product release criteria and will be used in a Phase 2 clinical trial for critical limb ischemia.
Kyriat Weizmann, Israel (PRWEB) April 22, 2014
Hemostemix, Ltd. (“Hemostemix,” the “Company”) announced today the issuance of a patent from the United States Patent and Trademark Office (U.S. Patent No. 8,685,724) entitled “In vitro techniques for use with stem cells.”
The patent pertains to the manufacture of the company’s therapeutic cell product from peripheral blood. The company’s lead product, manufactured using the methodologies disclosed in the patent, consists of a heterogenous mixture of cells, derived from a patient's peripheral blood collected by a simple blood draw.
The cells manufactured in accordance with the methodologies described in this newly issued patent meet specific product release criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence mid-year.
This patent, the second issued by the USPTO, is part of a broad technology platform now protected by over 40 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.
“The manufacturing processes which are the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “are an important pillar of our technology. This patent provides protection of the company’s manufacturing processes and further strengthens the company’s Intellectual Property in addition to the composition of matter patent that covers the actual cellular product, which was issued in the US in 2013.”
About Hemostemix Ltd
Hemostemix is a clinical-stage Canadian-Israeli company developing and commercializing innovative, autologous (patient’s own), blood-derived cell therapies to treat a variety of medical disorders not adequately address by current treatments. The Company is preparing to launch a phase 2 clinical trial of its lead product (ACP-01) in critical limb ischemia.
Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group. TVI has an agreement with Technical Ventures RX Corp (TSX-V:TIK.P) regarding a Qualifying Transaction in which TIK.P would acquire TVI in a share transaction. The two companies are working together to expedite this transaction. The directors of both TIK and TVI have approved this press release. For more information see http://www.hemostemix.com.